London, UK – 29 February 2012

Proximagen Initiates Phase I Trial of Oral VAP-1 antagonist.

2011 Annual Report

Proximagen’s 2011 Annual Report has been released.  To view the PDF, please click the link below.

Investor Relations

Our investor relations centre is provided to give you convenient access to company information.

Share Price

Proximagen Group plc (Ticker: PRX) is listed on the London Stock Exchange’s Alternative Investment Market.

Commitment to Science

Proximagen's commitment to science is fundamental. We strive for true scientific innovation in treatment.

Therapeutic Areas

Proximagen's aims to be one of the leading companies developing therapeutics in CNS, neuroinflammation, inflammation, and oncology.